Design Therapeutics reports $281.8M cash, new FA drug product DT-216P2, IND cleared for DT-168, new HD program

Design Therapeutics, Inc.

Net loss $11.8M in Q4 2023 and $66.9M for full year; cash & securities $281.8M funding 5-year runway.
New FA drug product DT-216P2 shows >10-fold improved PK and favorable injection site safety; GLP studies to complete by year-end 2024 for patient trials in 2025.
FDA cleared IND for DT-168 in FECD; Phase 1 to start in 2024; observational study of 200 patients underway.
New HD program targeting mutant HTT shows >50% selective reduction in brain striatum in preclinical studies.
DM1 GeneTAC molecules potently dial-down mutant DMPK, restore splicing; working toward development candidate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2023.

Period: the three and twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

On March 19, 2024, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-033475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.